Similar progression of fibrosis between HIV/HCV-infected and hcv-infected patients: Analysis of paired liver biopsy samples

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 12, 2010, Pages 1070-1076

  Sterling, Richard K ^a   Wegelin, Jacob A ^a   Smith, Paula G ^a   Stravitz, R Todd ^a   Luketic, Velimir A ^a   Fuchs, Michael ^a   Puri, Puneet ^a   Shiffman, Mitchell L ^a   Contos, Melissa A ^a   Mills, A Scott ^a   Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Coinfection; Hepatitis C Disease Progression; Human Immunodeficiency Virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBROSIS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; STEATOSIS; TREATMENT RESPONSE;

ADULT; BIOPSY; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 78649707481     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.08.004     Document Type: Article

References (37)

1. Lee L.M., Karon J.M., Selik R., et al. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001, 285:1308-1315.
2. Weber R., Sabin C.A., Friis-Møller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D: study. Arch Intern Med 2006, 166:1632-1641.
3. Sherman K.E., Rouster S.D., Chung R.T., et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 4:831-837.
4. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
5. Sobesky R., Lebray P., Nalpas B., et al. Pathologic evolution of hepatitis C virus-"healthy carriers.". World J Gastroenterol 2008, 14:3861-3865.
6. Ghany M.G., Kleiner D.E., Alter H., et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003, 124:97-104.
7. Ryder S.D., Irving W.L., Jones D.A., et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004, 53:451-455. Trent Hepatitis C Study Group.
8. Collier J.D., Woodall T., Wright D.G., et al. Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepatitis 2005, 12:74-80.
9. George S.L., Bacon B.R., Brunt E.M., et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5 year follow-up of 150 patients. Hepatology 2009, 49:729-738.
10. Benhamou Y., Bochet M., Di Martino V., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999, 30:1054-1058.
11. Mohsen A.H., Easterbrook P.J., Taylor C., et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003, 52:1035-1040.
12. Bräu N., Salvatore M., Ríos-Bedoya C.F., et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006, 44:47-55.
13. Sterling R.K., Contos M.J., Sanyal A.J., et al. The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr 2003, 32:30-37.
14. Benhamou Y., Di Martino V., Bochet M., et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001, 34:283-287.
15. Schiavini M., Angeli E., Mainini A., et al. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1885-2002. HIV Med 2006, 7:331-337.
16. Sarmento-Castro R., Horta A., Vasconcelos O., et al. Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection. J Infect 2007, 54:609-616.
17. Bani-Sadr F., Lapidus N., Bedossa P., et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008, 46:768-774.
18. Rodríguez-Torres M., Rodríguez-Orengo J.F., Ríos-Bedoya C.F., et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 2007, 46:613-619.
19. Pineda J.A., Macías J. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J Antimicrob Chemother 2005, 55:417-419.
20. Sterling R.K., Wilson M.S., Sanyal A.J., et al. Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection. Clin Gastroenterol Hepatol 2004, 2:432-439.
21. Bonnard P., Lescure F.X., Amiel C., et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat 2007, 14:806-811.
22. Macías J., Berenguer J., Japón M.A., et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009, 50:1056-1063.
23. McGovern B.H., Golan Y., Lopez M., et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007, 44:431-437.
24. Sulkowski M.S., Mehta S.H., Torbenson M.S., et al. Rapid fibrosis progression among HIV/hepatitis C virus co-infected adults. AIDS 2007, 21:2209-2216.
25. Thein H.H., Yi Q., Dore G.J., et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008, 22:1979-1991.
26. Souza A.R., Tovo C.V., Mattos A.A., et al. There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV. Braz J Med Biol Res 2008, 41:223-228.
27. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435.
28. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
29. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
30. Wai C.-T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
31. Sterling R.K., Lissen E., Clumeck N., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325.
32. Alberti A., Clumeck N., Collins S., et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005, 42:615-624.
33. Tien P.C. Veterans Affairs Hepatitis C Resource Center Program, National Hepatitis C Program Office Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol 2005, 100:2338-2354.
34. Sulkowski M.S. The HIV-coinfected patient: managing viral hepatitis. J Acquir Immune Defic Syndr 2007, 45(Suppl 2):S36-S37.
35. Sterling R.K. Role of liver biopsy in the evaluation of hepatitis C virus infection in HIV coinfection. Clin Infect Dis 2005, 40(Suppl 5):S270-S275.
36. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
37. Chung R.T., Andersen J., Volberding P., et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.